Emibetuzumab

Emibetuzumab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Eli Lilly and Company.

Mechanism of Action

Emibetuzumab is a monoclonal antibody that targets the MET receptor, also known as the hepatocyte growth factor receptor (HGFR). The MET receptor is often overexpressed in various types of cancer, including lung cancer, gastric cancer, and breast cancer. By binding to the MET receptor, emibetuzumab can inhibit the growth and proliferation of cancer cells.

Clinical Trials

Emibetuzumab has been evaluated in several clinical trials for its efficacy in treating various types of cancer. In a Phase II trial for non-small cell lung cancer, emibetuzumab showed promising results, with a significant number of patients experiencing a reduction in tumor size. However, further studies are needed to confirm these findings and to determine the optimal dosing regimen for this drug.

Side Effects

Like all drugs, emibetuzumab can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and diarrhea. Less common but more serious side effects can include liver damage, lung problems, and infusion reactions. Patients should discuss the potential risks and benefits of emibetuzumab with their healthcare provider before starting treatment.

See Also

• Monoclonal antibodies
• Cancer treatment
• Eli Lilly and Company
• Clinical trials
• Side effects

References

Emibetuzumab Resources
Latest articles Most recent articles Ongoing trials	Wikipedia